Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Narcan Nasal

Last reviewed on RxList: 1/17/2019
Narcan Nasal Side Effects Center

Last reviewed on RxList 1/17/2019

Narcan (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Narcan Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Common side effects of Narcan Nasal Spray include:

  • increased blood pressure,
  • musculoskeletal pain,
  • headache,
  • nasal dryness,
  • nasal swelling,
  • nasal congestion, and
  • nasal inflammation

The dose of Narcan Nasal Spray is 4 mg of naloxone hydrochloride in 0.1 mL nasal spray. Narcan Nasal Spray may interact with buprenorphine, pentazocine, and other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before using Narcan Nasal Spray. Infants born to mothers who use opioids like Narcan Nasal Spray during pregnancy may have withdrawal symptoms. It is unknown how Narcan Nasal Spray may affect a nursing infant. Consult your doctor before breastfeeding. Withdrawal symptoms may occur if you suddenly stop taking Narcan Nasal Spray.

Our Narcan (naloxone hydrochloride) Nasal Spray Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Addicted to Pills: The Health Risks of Drug Abuse See Slideshow
Narcan Nasal Professional Information

SIDE EFFECTS

The following serious adverse reactions are discussed elsewhere in the labeling:

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice. The following adverse reactions were observed in a NARCAN Nasal Spray clinical study.

In a pharmacokinetic study of 30 healthy adult volunteers exposed to one spray of NARCAN Nasal Spray in one nostril or two sprays of NARCAN Nasal Spray, one in each nostril, the most common adverse reactions were: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

The following adverse reactions have been identified primarily during post-approval use of naloxone hydrochloride in the post-operative setting. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. Excessive doses of naloxone hydrochloride in post-operative patients have resulted in significant reversal of analgesia, and have caused agitation.

Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated an acute withdrawal syndrome. Signs and symptoms have included: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. In the neonate, opioid withdrawal signs and symptoms also included convulsions, excessive crying, and hyperactive reflexes.

Read the entire FDA prescribing information for Narcan Nasal (Naloxone Hydrochloride Nasal Spray)

Related Resources for Narcan Nasal

© Narcan Nasal Patient Information is supplied by Cerner Multum, Inc. and Narcan Nasal Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW